# OnCo record paper-yarden-sliwkowski-erbb-network-nrmcb-2001 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-yarden-sliwkowski-erbb-network-nrmcb-2001/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-yarden-sliwkowski-erbb-network-nrmcb-2001" ;
  schema:name "Yarden and Sliwkowski 2001: untangling the ErbB signalling network"@en ;
  schema:description "The classic account of the HER family of receptors, explaining why HER2 is such a powerful cancer driver: it is the preferred partner for the other three receptors and turns their signals up, which is what trastuzumab and later HER2 drugs exploit."@en ;
  schema:url <https://onco.cc/key-papers/paper-yarden-sliwkowski-erbb-network-nrmcb-2001/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:citation <https://doi.org/10.1038/35052073> ;
  schema:sameAs <https://doi.org/10.1038/35052073> ;
  schema:datePublished "2001"^^xsd:gYear ;
  schema:author "Yarden Y, Sliwkowski MX." ;
  onco:related <https://onco.cc/key-papers/paper-lemmon-schlessinger-rtk-signalling-cell-2010/>, <https://onco.cc/key-papers/paper-slamon-her2-amplification-science-1987/> ;
  onco:targets <https://onco.cc/targets/egfr/>, <https://onco.cc/targets/her2/>, <https://onco.cc/targets/her3/>, <https://onco.cc/targets/erbb4/> ;
  onco:companies <https://onco.cc/companies/roche-genentech/> ;
  onco:pathways <https://onco.cc/pathways/rtk-activation/> .